Ever since Xconomy added New York to its stable of cities on April 1, we have found plenty of companies to write about that are making waves in tech, biotech, and cleantech. We’ve met tech entrepreneurs who’ve caught the fancy of New York’s thriving venture capital scene, and scientists in the bowels of Big Pharma laboring to invent the next blockbuster drugs. We’ve visited with CEOs in the rapidly growing biotech sector in and around NYC, and profiled so many new startup incubators we’ve lost count of them all.
To wrap up our first (partial) year in the Big Apple, we’re counting down the top 10 Xconomy topics, as measured by traffic. Why topics as opposed to stories? You’ll have to read all the way to the end to find out.
Our most popular topics of the year were….
10. Arno Therapeutics
Arno (OTCBB: ARNI), based in Parsippany, NJ, is what’s known as a “virtual biotech,” because it’s developing three drugs with just a handful of full-time employees who outsource almost every step of the research and development process. But it’s a mighty qualified handful—Arno is staffed by veterans of Johnson & Johnson, Pfizer, and Medimmune.
When New York’s leaders put out a request for proposals for a tech incubator in Harlem, entrepreneurs Marcus Mayo and Brian Shields responded with IncubateNYC, a multifaceted plan to bring technology startups to an area of the city that could use an economic revival.
The pharmaceutical industry is desperate for new technology to improve drug discovery. Pennington, NJ-based BioLeap believes it has a solution in a tech platform designed to predict how tightly experimental drugs will bind to their disease targets.
What do you get when you combine social media with financial services? Lenddo believes you get a great way to market small loans to the developing world’s emerging middle class.
NYC-based medical device maker Delcath Systems (NASDAQ: DCTH) has endured endless hassles from the FDA over its drug-device combo to treat liver cancer, and investors have been bailing outin droves. But the company is preparing to launch the product in Europe—a move its management team hopes will signal the beginning of a turnaround.
5. Everyday Health
This online aggregator of popular health brands—ranging from What to Expect to South Beach Diet—is expanding big time into social media, apps, and television. With over $100 million in annual revenues, this company is gunning to become the next big health-information media brand.
4. MongoDB Wizards
Xconomy takes a look at the plethora of companies building “NoSQL” databases, including New York and Redwood Shores, CA-based 10gen, which has raised $31 million in venture capital since September.
Berkeley Heights, NJ-based Cyclacel (NASDAQ: CYCC) is developing a drug to treat acute myeloid leukemia. But the company has struggled and investors are losing patience: Its share price has fallen from $1.63 when we ran our story in May to 48 cents.
2. Steve Jobs
Xconomy welcomes contributions from guest writers, and healthcare analyst Christopher Bowe clearly hit a nerve in the days following Apple CEO Steve Jobs’ passing with his piece for our Xconomist Forum, “The Essential Steve Jobs for Today’s Pharmaceutical Executive.” Bowe argues that pharma CEOs could learn a thing or two about innovation from Jobs’ time at Apple.
Yes it’s true, three stories about drug giant Merck (NYSE: MRK) attracted more traffic than any other posts on Xconomy New York this year. Readers were clearly interested in the Whitehouse Station, NJ-based company’s plans to increase shareholder value with a variety of strategies, ranging from pursuing biosimilars to launching an all-out attack on Alzheimer’s disease.
Judging from our readers’ choices in our first year online, it seems fair to say the future of innovation rests on everyone’s shoulders—from established players like Merck to upstarts like IncubateNYC. Watch this space in 2012 for more great stories about invention, inspiration, and ingenuity in and around the Big Apple.
By posting a comment, you agree to our terms and conditions.